Delhi High Court Greenlights Zydus's Cheaper Cancer Drug, Nivolumab Biosimilar 70% Off

• Delhi High Court allows Zydus Lifesciences to sell a biosimilar of Bristol Myers Squibb's expensive cancer drug 'Nivolumab'.
• Zydus's biosimilar, ZRC 3276, is 70% cheaper than the original 'Nivolumab' (Opdiva).
• The court emphasized public welfare over patent rights for life-saving drugs, lifting a previous stay on sales.
• This decision significantly reduces healthcare costs for cancer patients, making treatment more accessible.
• Nivolumab is a crucial immunotherapy drug used for lung cancer, kidney cancer, and melanoma.

Why It Matters: Delhi High Court's ruling makes a vital cancer drug 70% cheaper, prioritizing public health over patent rights.